Evidence map›Paper›PMID 41918857›Full record

ArticlePeerJ2026

MetaPepticon: automated prediction of anticancer peptides from microbial genomes and metagenomes.

Ahmet Arıhan Erözden, Nalan Tavşanlı, Gamze Demirel, Nazmiye Ozlem Sanli, Mahmut Çalışkan, Muzaffer Arıkan

Abstract read
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmet Arıhan ErözdenBiotechnology Division, Department of Biology, Faculty of Science, Istanbul University, Istanbul, Turkey.
Nalan TavşanlıBiotechnology Division, Department of Biology, Faculty of Science, Istanbul University, Istanbul, Turkey.
Gamze DemirelInstitute of Graduate Studies in Science, Istanbul University, Istanbul, Turkey.
Nazmiye Ozlem SanliBiotechnology Division, Department of Biology, Faculty of Science, Istanbul University, Istanbul, Turkey.
Mahmut ÇalışkanBiotechnology Division, Department of Biology, Faculty of Science, Istanbul University, Istanbul, Turkey.
Muzaffer ArıkanBiotechnology Division, Department of Biology, Faculty of Science, Istanbul University, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anticancer peptides (ACPs) are increasingly recognized as promising therapeutic candidates due to their ability to selectively target cancer cells. However, the systematic discovery of novel ACPs, particularly from high-throughput sequencing datasets, remains hindered by technical and methodological limitations. Current prediction frameworks require pre-extracted peptide sequences, involve manual preprocessing, and yield variable results, which restricts their applicability for large-scale, data-driven discovery. Methods: To address these limitations, we developed MetaPepticon, a modular, end-to-end pipeline for the discovery of ACP candidates from diverse sequencing inputs, including raw genomic, metagenomic, transcriptomic, and metatranscriptomic reads, as well as assembled contigs and peptide sequences. MetaPepticon automates quality control, filtering, assembly, small open reading frame prediction, ACP classification using multiple predictive algorithms, and Results: MetaPepticon enables scalable and reproducible ACP prediction from raw sequences through integration of multiple predictors within a configurable agreement framework. Applied to 41,171 microbial genomes and 4,072,884 peptides, MetaPepticon identified 10,725 moderate-agreement ACP candidates, including 4,590 novel, non-toxic peptides. MetaPepticon expands the practical applicability of existing ACP prediction methods to high-throughput sequencing data and is freely available at: https://github.com/arikanlab/MetaPepticon.

Indexed as

Antineoplastic AgentsGenome, MicrobialMetagenomePeptidesAlgorithmsComputational BiologyHigh-Throughput Nucleotide SequencingHumansPrediction AlgorithmsSoftwareAntineoplastic AgentsPeptidesAnticancer peptideBioinformaticsGenomicsMetagenomicsMicrobiome

Identifiers

PMID41918857
PMCPMC13034871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.